Erschienen in:
16.06.2019 | Original Article
Outcome of postoperative radiation therapy for pediatric intracranial ependymoma: a single-institution review
verfasst von:
Rawee Ruangkanchanasetr, Thiti Swangsilpa, Putipun Puataweepong, Mantana Dhanachai, Ake Hansasuta, Atthaporn Boongird, Nongnuch Sirachainan, Suradej Hongeng
Erschienen in:
Child's Nervous System
|
Ausgabe 8/2019
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To report outcome of postoperative radiotherapy (RT) in both new and recurrent grade II and III intracranial ependymomas in children treated at Ramathibodi Hospital.
Materials and methods
Between 2006 and 2017, 24 pediatric intracranial ependymomas treated with postoperative RT were retrospectively reviewed. The median age at diagnosis was 44.5 months (range, 4–165 months). There were 14 (58%) males. Fourteen (58%) patients had infratentorial tumor. The median maximal diameter of tumor at diagnosis was 4.45 cm (range, 2.2–10 cm). Fourteen (58%) patients had anaplastic tumor. Gross total resections were performed in 14 (58%) patients. The median prescribed dose was 54 Gy (range, 45–60 Gy). The median total treatment time was 43 days (range, 37–78 days).
Results
The median clinical follow-up time was 44.5 months (range, 1–146 months). There were nine recurrences, five of which occurred at the primary tumor site. The estimated 5-year progression-free survival rate was 56%. The estimated 5-year overall survival rate was 75%. Extent of resection was the only factor associated with improved progression-free survival and overall survival after univariate testing. Six from nine patients with recurrent diseases underwent further surgery or further RT. These six patients had better median overall survival than the three who did not. Acute complication was mostly transient and tolerable. No late radiation effect was found.
Conclusions
Postoperative radiation is an effective treatment. GTR is associated with better PFS and OS. Aggressive salvage local treatments for recurrent patients can result in good overall survival. Longer follow-up is needed in account for late relapse.